Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...

Gilead’s potential investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor ...

The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the ...

Morgan Stanley upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from an equal weight rating to an overweight rating in a research note published on Friday, MarketBeat.com reports. Morgan ...

Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...

Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...

Harbor Capital Advisors Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.3% during the 4th ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...